血清胱抑素C、尿酸与不同射血分数慢性心衰患者相关性研究进展
Research Progress between Cystatin C Levels and Uric Acid of Heart Failure Patients with Different Left Ventricular Ejec-tion Fractions
摘要: 慢性心力衰竭是心血管疾病发展到晚期的一种复杂临床综合征，其5年生存率与恶性肿瘤相似，已成为危害人类健康的主要疾患之一。现阶段，临床诊断慢性心力衰竭的实验室指标仍以脑钠肽为主，随着临床研究的深入，血清胱抑素C及尿酸为心力衰竭的早期诊断带来新的曙光。本文综述了心力衰竭诊断的参考指标，以期为临床诊断慢性心力衰竭提供参考依据。
Abstract: Chronic heart failure is a complex clinical syndrome in the late stage of cardiovascular disease. Its 5-year survival rate is similar to that of malignant tumors. It has become one of the major diseases endangering human health. At this stage, the laboratory index of clinical diagnostics of chronic heart failure is still based on B-type Natriuretic Peptide. With the deepening of clinical research, cystatin C levels and uric acid bring new dawn to the diagnostics of heart failure. This article reviews the diagnostics for heart failure, in order to provide reference for clinical diagnostics of chronic heart failure.
文章引用：岳怡彤, 岳怀献, 高燕. 血清胱抑素C、尿酸与不同射血分数慢性心衰患者相关性研究进展[J]. 临床医学进展, 2023, 13(7): 11215-11220. https://doi.org/10.12677/ACM.2023.1371566

参考文献

[1] Ma, L.Y., Chenw, W., Gao, R.L., et al. (2020) China Cardiovascular Diseases Report 2018: An Updated Summary. Journal of Geriatric Cardiology, 17, 1-8.
[2] Lim, S., Despres, J.E. and Koh, K.K. (2011) Prevention of Atherosclero-sis in Overweigh/Obese Patients. In Need of Novel Multi-Targeted Approaches. Circulation Journal, 75, 1019-1027. [Google Scholar] [CrossRef] 
[3] 马丽媛, 吴亚哲, 陈伟伟. 《中国心血管病报告2018》要点介绍[J]. 中华高血压杂志, 2019, 27(8): 712-716.
[4] 国家心血管病中心. 中国心血管病报告2018[M]. 北京: 中国大百科全书出版社, 2018.
[5] 陈伟伟, 高润霖, 刘力生, 等. 中国心血管病报告2014概要[J]. 中国循环杂志, 2015, 30(7): 617-622.
[6] 于彤彤. 慢性心力衰竭患者在临床特点及危险因素方面的性别差异[J]. 山东医药, 2015, 55(12): 49-51.
[7] 张徽, 齐书英, 曹士考, 等. 心脏再同步治疗对不同病因心力衰竭的短期疗效[J]. 解放军医药杂志, 2014, 25(9): 17-20.
[8] Gerber, Y., Weston, S.A., Redfield, M.M., et al. (2015) A Contemporary Ap-praisal of the Heart Failure Epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Internal Medicine, 175, 996-1004. [Google Scholar] [CrossRef] [PubMed]
[9] 马文君, 马涵萍, 王运红, 等. 《2021年中国心血管病医疗质量报告》概要[J]. 中国循环杂志, 2021, 36(1): 1000-3614(2021)11-1041-24
[10] 中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志, 2018, 46(10): 760.
[11] 弓孟春, 严晓伟. 欧洲心脏病学会2008年版心力衰竭的诊断和治疗指南解读[J]. 中国实用内科杂志, 2009, 29(8): 703-706.
[12] Johannes, C., Martin, K., Theresa, A., et al. (2011) Quantifying the Added Value of BNP in Suspected Heart Failure in General Practice: An Individual Patient Data Meta-Analysis. Heart, 97, 959-963. [Google Scholar] [CrossRef] [PubMed]
[13] 陈志奎, 葛长江, 胡申江. 胱抑素C与管疾病的关系[J]. 生理科学进展, 2003, 34(3): 269-271.
[14] Ristiniemi, N. (2012) Cystatin C as a Predictor of All-Cause Mortality and Myo-cardial Infarction in Patients with Non-ST-Elevation Acute Coronary Syndrome. Clinical Biochemistry, 45, 535-540. [Google Scholar] [CrossRef] [PubMed]
[15] De Silva, R., Nikitin, N.P., Witte, K.K., et al. (2006) Inci-dence of Renal Dysfunction over 6 Months in Patients with Chronic Heart Failure Due to Left Ventricular Systolic Dys-function: Contributing Factors and Relationship to Prognosis. European Heart Journal, 27, 569-581. [Google Scholar] [CrossRef] [PubMed]
[16] Damman, K., Navis, G., Voors, A.A., et al. (2007) Worsening Renal Function and Prognosis in Heart Failure: Systematic Review and Meta-Analysis. Journal of Cardiac Failure, 13, 599-608. [Google Scholar] [CrossRef] [PubMed]
[17] 史钰芳, 陈士金, 王庆海, 等. NT-proBNP与CysC对慢性心力衰竭患者心功能及左室重构的影响[J]. 心脑血管病防治, 2017, 17(2): 119-121.
[18] Zappitelli, M., Greenberg, J.H., Coca, S.G., et al. (2015) Association of Definition of Acute Kidney Injury by Cystatin C Rise with Biomarkers and Clinical Outcomes in Children Undergoing Cardiac Surgery. JAMA Pediatrics, 169, 583-591. [Google Scholar] [CrossRef] [PubMed]
[19] Salgado, J.V., Neves, F.A., Bastos, M.G., et al. (2010) Moni-toring Renal Function: Measured and Estimated Glomerular Filtration Rates—A Review. Brazilian Journal of Medical and Biological Research, 43, 528-536. [Google Scholar] [CrossRef] 
[20] 王文丰, 金大鹏, 巨名飞, 等. 介入治疗对合并糖尿病的老年急性心肌梗死患者心脏功能影响的临床研究[J]. 河北医学, 2017(8): 1301-1304.
[21] 殷和, 王琼, 巩婷, 等. 血清CysC测定在心力衰竭患者预后状况判定中的临床意义研究[J]. 中国实验诊断学, 2016, 20(3): 437-438.
[22] 李宾, 刘静, 黄红霞, 等. Galectin-3和CysC水平与慢性心力衰竭患者心室重构及预后关系的研究[J]. 宁夏医科大学学报, 2015, 37(3): 252-256.
[23] 闫秋芬. 胱抑素C与高血压患者心肌纤维化及左室舒张功能的相关性研究[J]. 中国医师进修杂志, 2012, 35(16): 61-63.
[24] 杨光, 姚晓伟, 梁磊, 等. 冠心病患者CysC､02MG水平与患者左心结构及功能的相关性分析[J]. 中国循证心血管医学杂志, 2017, 9(6): 745-747.
[25] Wood, A.D., Gollop, N.D., Bettencourt-Silva, J.H., et al. (2016) A6-Point TACS Score Predicts in Hospital Mortality Follow-ing Total Antenor Circulation Stroke. Journal of Clinical Neurology, 12, 407-413. [Google Scholar] [CrossRef] [PubMed]
[26] 田晓棠. 胱抑素C、尿微量白蛋白/尿肌酐比值在慢性充血性心力衰竭中的变化及临床意义[D]: [硕士学位论文]. 太原: 山西医科大学, 2012: 12.
[27] 张少利, 王学惠, 陈志刚, 等. 慢性心力衰竭患者血清胱抑素C水平与疾病严重程度及预后的相关性研究[J]. 解放军医药杂志, 2017, 29(3): 46-48.
[28] 吴晓东, 齐新, 侯文广, 等. 慢性心力衰竭患者血清胱抑素C水平变化及临床意义[J]. 天津医药, 2015, 43(10): 1162-1165.
[29] 洪冰, 付爱真. 保留射血分数的慢性心衰血清胱抑素C水平与心室重塑的相关性研究[J]. 内蒙古医学杂志, 2021, 53(5): 542-547.
[30] Huerta, A., Lopez, B., Ravassa, S., et al. (2016) Association of Cystatin C with Heart Failure with Preserved Ejection Fraction in Elderly Hypertensive Patients: Potential Role of Altered Collagen Metabolism. Journal of Hypertension, 34, 130-138. [Google Scholar] [CrossRef] 
[31] 余碧菁. 慢性射血分数降低心力衰竭患者血清胱抑素C水平变化及意义[D]: [硕士学位论文]. 福州: 福建医科大学, 2015.
[32] Cidade-Rodrigues, C., Cunha, F.M., Elias, C., et al. (2021) The prognostic Impact of Uric Acid in Acute Heart Failure According to Coexistence of Diabetes Mellitus. Nutrition, Metabolism and Cardiovascular Diseases, 31, 3377-3383. [Google Scholar] [CrossRef] [PubMed]
[33] Selvaraj, S., Claggett, B.L., Pfeffer, M.A., et al. (2020) Serum Uric Acid, Influence of Sacubitril-Valsartan, and Cardiovascular Outcomes in Heart Failure with Preserved Ejection Fraction: PAR-AGON-HF. European Journal of Heart Failure, 22, 2093-2101. [Google Scholar] [CrossRef] [PubMed]
[34] Si, K., Wei, C., Xu, L., et al. (2021) Hyperuricemia and the Risk of Heart Failure: Pathophysiology and Therapeutic Implications. Frontiers in Endocrinology (Lausanne), 12, Article ID: 770815. [Google Scholar] [CrossRef] [PubMed]
[35] 王小红, 王丽. 不同射血分数心力衰竭患者黄嘌呤氧化酶与尿酸的表达及意义[J]. 实用医学杂志, 2022, 38(10): 1231-1235.
[36] Yu, W. and Cheng, J.D. (2020) Uric Acid and Cardiovascular Disease: An Update from Molecular Mechanism to Clinical Perspective. Frontiers in Pharmacology, 11, Article ID: 582680. [Google Scholar] [CrossRef] [PubMed]
[37] Joshi, G., Sharma, M., Kalra, S., et al. (2021) Design, Synthesis, Biological Evaluation of 3,5-Diaryl-4,5-dihydro- 1H-pyrazole Carbaldehydes as Non-Purine Xanthine Oxidase Inhibitors: Tracing the Anticancer Mechanism via Xanthine Oxidase Inhibition. Bioorganic Chemistry, 107, Ar-ticle ID: 104620. [Google Scholar] [CrossRef] [PubMed]
[38] Sakuma, M., Toyoda, S., Arikawa, T., et al. (2018) The Effects of Xanthine Oxidase Inhibitor in Patients with Chronic Heart Failure Complicated with Hyperuricemia: A Prospective Randomized Controlled Clinical Trial of Topiroxostat vs Allopurinol—Study Protocol. Clinical and Ex-perimental Nephrology, 22, 1379-1386. [Google Scholar] [CrossRef] [PubMed]
[39] Cicero, A.F.G., Fogacci, F., Cincione, R.I., et al. (2021) Clinical Effects of Xanthine Oxidase Inhibitors in Hyperuricemic Patients. Medical Principles and Practice, 30, 122-130. [Google Scholar] [CrossRef] [PubMed]
[40] Sakai, H., Teutamoto, T., Tsutsui, T., et al. (2006) Serum Level of Uric Acid, Partly Secreted from the Failing Heart, Is a Prognostic Marker in Patients with Congestive Heart Failure. Circula-tion Journal, 70, 1006-1011. [Google Scholar] [CrossRef] [PubMed]
[41] Tamariz, L., Harzand, A., Palacio, A., et al. (2011) Uric Acid as a Pre-dictor of All-Cause Mortality in Heart Failure: A Meta Analysis. Congestive Heart Failure, 17, 25-30. [Google Scholar] [CrossRef] [PubMed]
[42] Hamaguchi, S., Furumoto, T., Tsuchihashi-Makaya, M., et al. (2011) Hyperuricemia Predicts Adverse Outcomes in Patients with Heart Failure. International Journal of Cardiology, 151, 143-147. [Google Scholar] [CrossRef] [PubMed]
[43] Huang, H., Huang, B., Li, Y., et al. (2014) Uric Acid and Risk of Heart Failure: A Systematic Review and Meta- Analysis. European Journal of Heart Failure, 16, 15-24. [Google Scholar] [CrossRef] [PubMed]
[44] Mrug, S., Mrug, M., Morris, A.M., et al. (2017) Uric Acid Excretion Predicts Increased Blood Pressure among American Adolescents of African Descent. The American Journal of the Med-ical Sciences, 353, 336-341. [Google Scholar] [CrossRef] [PubMed]
[45] 曹丹丹, 张菲斐, 韩战营, 邱春光, 黄振文. 不同类型心力衰竭患者血尿酸与NT-proBNP、hs-CRP的关系[J]. 临床心血管病杂志, 2014, 29(6): 417-419.
[46] Kanellis, J. and Kang, D.H. (2005) Uric Acid as a Mediator of Endothelial Dysfunction, Inflammation, and Vascular Disease. Seminars in Nephrology, 25, 39-42. [Google Scholar] [CrossRef] [PubMed]
[47] 周浩斌, 安冬琪, 詹琼, 等. 不同射血分数心力衰竭患者临床特征和预后的回顾性分析[J]. 中华内科学杂志, 2017, 56(4): 253-257.
[48] Presta, V., Citoni, B. and Tocci, G. (2019) Xanthine Oxidase Inhibitors in Elderly Patients with Heart Failure: Useful or Useless. Internal and Emergency Medicine, 14, 903-905. [Google Scholar] [CrossRef] [PubMed]
[49] Belfiore, A., Palmieri, V.O., Di Gennaro, C., et al. (2020) Long-Term Management of Chronic Heart Failure Patients in Internal Med-icine. Internal and Emergency Medicine, 15, 49-58. [Google Scholar] [CrossRef] [PubMed]

为你推荐